A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score
暂无分享,去创建一个
P. Prandoni | D. Tormene | F. Noventa | A. Pagnan | S. BARBAR | F. NOVENTA | V. ROSSETTO | A. FERRARI | B. BRANDOLIN | M. PERLATI | E. DE BON | D. TORMENE | A. PAGNAN | P. PRANDONI | V. Rossetto | S. Barbar | E. De Bon | M. Perlati | B. Brandolin | A. Ferrari | Marica Perlati | E. Bon
[1] P. D. de Groot,et al. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment , 2011, Journal of internal medicine.
[2] A. Turpie,et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.
[3] S. Goldhaber,et al. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. , 2004, The American journal of cardiology.
[4] T. Wakefield,et al. Call to action to prevent venous thromboembolism. , 2009, Journal of vascular surgery.
[5] V. Hach-Wunderle,et al. An Evaluation of Venous Thromboembolic Risk in Acutely Ill Medical Patients Immobilized at Home: The AT-HOME Study , 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[6] J. Paramo,et al. Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalized patients , 2008, Thrombosis and Haemostasis.
[7] L. Mazzolai,et al. Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] C. Francis. Prophylaxis for Thromboembolism in Hospitalized Medical Patients , 2007 .
[9] A. D’Angelo,et al. Potential failure of the International Normalized Ratio (INR) System in the monitoring of oral anticoagulation in patients with lupus anticoagulants. , 1996, Annales de medecine interne.
[10] D. Hayoz,et al. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement , 2005, Journal of internal medicine.
[11] Pieter W Kamphuisen,et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. , 2006, JAMA.
[12] I. Mackie,et al. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti‐phospholipid syndrome , 1997, British journal of haematology.
[13] M. Prins,et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.
[14] G. Reber,et al. Control of Oral Anticoagulation in Patients with the Antiphospholipid Syndrome – Influence of the Lupus Anticoagulant on International Normalized Ratio , 1998, Thrombosis and Haemostasis.
[15] P. Mannucci,et al. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins , 2001, British journal of haematology.
[16] E. Oger,et al. Venous thromboembolism (VTE) in Europe , 2007, Thrombosis and Haemostasis.
[17] Samuel Z Goldhaber,et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study , 2008, The Lancet.
[18] J. Kahan,et al. An electronic tool for venous thromboembolism prevention in medical and surgical patients. , 2006, Haematologica.
[19] S. Iliceto,et al. Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome , 2010, Journal of thrombosis and haemostasis : JTH.
[20] A. Turpie,et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients , 2005, Thrombosis and Haemostasis.
[21] Lain,et al. A COMPARISON OF ENOXAPARIN WITH PLACEBO FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS , 2000 .
[22] E. Vicaut,et al. Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility , 2010, Annals of Internal Medicine.
[23] J. Douketis,et al. The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism , 2007, Annals of Internal Medicine.
[24] T. Ortel,et al. Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.
[25] G. Geroulakos,et al. Prevention and Treatment of Venous Thromboembolism , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[26] Jonathan Dreyer,et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. , 2003, The New England journal of medicine.
[27] P. Chopard,et al. Identifying acutely ill medical patients requiring thromboprophylaxis , 2006, Journal of thrombosis and haemostasis : JTH.
[28] Marilyn D Paterno,et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. , 2005, The New England journal of medicine.
[29] A. Nicolaides,et al. Prevention and treatment of venous thromboembolism - International Consensus Statement (Guidelines according to scientific evidence) , 2006 .
[30] P. Prandoni,et al. Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients , 2008, British journal of haematology.
[31] L. Melton,et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. , 2002, Archives of internal medicine.
[32] M. Morel-Kopp,et al. False‐negative or false‐positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant , 2010, Journal of thrombosis and haemostasis : JTH.
[33] Mark Crowther,et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[34] C. Marosi,et al. Prediction of venous thromboembolism in cancer patients. , 2010, Blood.
[35] J. Raffetto. Call to action to prevent venous thromboembolism , 2010 .
[36] J. Heit,et al. Risk factors for venous thromboembolism. , 2003, Clinics in chest medicine.
[37] A. Turpie,et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. , 2007, Chest.
[38] S. Goldhaber,et al. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. , 2000, Chest.
[39] S. Goldhaber,et al. Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.
[40] Clifford W Colwell,et al. Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .